Serologic Response to SARS-CoV-2 Vaccine in Patients with Breast Cancer

Aysun Işıklar; Gül Başaran; Ozde Melisa Celayir; Gülçin Kahraman; Jameela Somanje; Semra Öykü Çolak; Mustafa Serteser; Nurdan Tozun

doi:10.31067/acusaglik.1247538

EN

Serologic Response to SARS-CoV-2 Vaccine in Patients with Breast Cancer

Abstract

Background: Our study aimed to measure effectiveness of Anti-S1 RBD (receptor binding domain) IgG Antibody levels against SARS (severe acute respiratory syndrome) Cov-2 in breast cancer patients and compare them with healthy participants. Methods: This prospective cross-sectional, single-center study was designed to evaluate Anti-S1 RBD IgG antibody levels following SARS-CoV-2 vaccination in 54 breast cancer patients and 56 healthy controls without cancer diagnosis. Results: Anti-S1 RBD IgG antibody test was positive in 79.6% (43/54) of breast cancer patients, in 92.9% (52/56) of participants in the control group (p=0.054) and, 63.3% in breast cancer patients who were on chemotherapy+/-molecularly targeted therapy following at least two doses of vaccinations. Hybrid vaccination (use of two different types of vaccines) and more than two doses of vaccinations were associated with higher antibody titers both in patient and control groups. Median time to vaccination was 123 days (8-427) in the entire group and was significantly associated with antibody titer. Among breast cancer patients, type and frequency of vaccination, age and use of cytotoxic therapies were significantly associated with the magnitude of antibody response to SARS-CoV-2 vaccination in our study. Conclusion: Breast cancer patients developed a lower antibody response to vaccination against COVID-19 in comparison to healthy subjects. Clinical and treatment related factors might help in tailoring future vaccination strategies for specific subsets of breast cancer patients.

Keywords

Supporting Institution

Acıbadem Mehmet Ali Aydınlar Üniversitesi Araştırma Projeleri Ofisi

Project Number

2021-13/7

Thanks

Acıbadem Mehmet Ali Aydınlar Üniversitesi Araştırma Projeleri Ofisine

References

WHO (Internet). Available form: https://www.who.int/westernpacific/health-topics/detail/coronavirus? (Accessed 06 June 2021)
Citgez B, Yigit B, Capkinoglu E, Yetkin SG. Management of Breast Cancer during the COVID-19 Pandemic. Sisli Etfal Hastan Tip Bul. 2020;54(2):132-135. Available from: doi:10.14744/SEMB.2020.23326
Kuderer, NM, Choueiri TK., Shah, DP, Shyr Y, Rubinstein SM, Rivera DR et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study (published correction appears in Lancet. 2020 Sep 12;396(10253):758). Lancet. 2020;395(10241):1907-1918. Available from: doi:10.1016/S0140-6736(20)31187-9
Fendler A, Shepherd S, Au L, Wilkinson KA, Wu M, Byrne F et al. Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study. Nat Cancer. 2021;2:1321-1337. Available from: doi:10.1038/s43018-021-00274-w
Thomas SJ, Moreira ED Jr, Kitchin N, Absalon J, Gurtman A, Lockhart S et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N Engl J Med. 2021;385(19):1761-1773. Available from: doi:10.1056/NEJMoa2110345
Massarweh, A, Eliakim-Raz N, Stemmer A., Levy-Barda A, Yust-Katz S, Zer A et al. Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer. JAMA Oncol. 2021;7(8):1133-1140. Available from: doi:10.1001/jamaoncol.2021.2155
Earle KA, Ambrosino DM, Fiore-Gartland A, Goldblatt D, Gilbert PB, Siber GR et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine. 2021;39(32):4423-4428. Available from: doi: 10.1016/j.vaccine.2021.05.063
Tian X, Jiang W, Zhang H, Lu X, Li L, Liu W et al. Persistence of the SARS-CoV-2 Antibody Response in Asymptomatic Patients in Correctional Facilities. Front Microbiol. 2021; 12:789374. Available from: doi:10.3389/fmicb.2021.789374

Lee A, Wong SY, Chai L, Lee SC, Lee MX, Muthiah MD et al. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ. 2022;376: e068632. Available from: doi:10.1136/bmj-2021-068632
Del Bello A, Abravanel F, Marion O, Couat C, Esposito L, Lavayssière L et al. Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients. Am J Transplant. 2022;22(1):322-323. Available from: doi:10.1111/ajt.16775
Wise J. Covid-19: UK will offer third vaccine dose to severely immunosuppressed people. BMJ. 2021; 374: n2160. Available from: doi: 10.1136/bmj.n2160
Irsara C, Egger AE, Prokop W, Nairz M, Loacker L, Sahanic S et al. Clinical validation of the Siemens quantitative SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers. Clin Chem Lab Med. 2021;59(8):1453-1462. Available from: doi:10.1515/cclm-2021-0214
National Institutes of Health. COVID-19 Treatment Guidelines. Anti-SARS-CoV-2 Antibody Products. Convalescent Plasma. Last update: October 9, 2020. Available from: https://www.covid19treatmentguidelines.nih.gov/anti-sars-cov-2- antibody-products/convalescent-plasma. (Accessed 06 June 2021)
Karacin C, Eren T, Zeynelgil E, Imamoglu GI, Altinbas M, Karadag I, et al. Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy. Future Oncology 2021 17:33, 4447-4456. Available from: doi:10.2217/fon-2021-0597
Yasin AI, Aydin SG, Sümbül B, Koral L, Şimşek M, Geredeli Ç et al. Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study. Future Oncol. 2022;18(10):1235-1244. Available from: doi:10.2217/fon-2021-1248
Linardou H, Spanakis N, Koliou GA, Christopoulou A, Karageorgopoulou S, Alevra N et al. Responses to SARS-CoV-2 Vaccination in Patients with Cancer (ReCOVer Study): A Prospective Cohort Study of the Hellenic Cooperative Oncology Group. Cancers (Basel). 2021;13(18):4621. Available from: doi:10.3390/cancers13184621
Grinshpun A, Rottenberg Y, Ben-Dov IZ, Djian E, Wolf DG, Kadouri L. Serologic response to COVID-19 infection and/or vaccine in cancer patients on active treatment. ESMO Open. 2021;6(6):100283. Available from: doi:10.1016/j.esmoop.2021.100283
Thakkar, A., Gonzalez-Lugo, J. D., Goradia, N., Gali, R., Shapiro, L. C., Pradhan, K., et al. Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell. 2021;39(8):1081-1090.e2. Available from: doi:10.1016/j.ccell.2021.06.002
Addeo A, Shah PK, Bordry N, Hudson RD, Albracht B, Marco MD, et al. Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer. Cancer Cell. 2021;39(8):1091-1098.e2. Available from: doi:10.1016/j.ccell.2021.06.009
Barrière, J., Carles, M., Audigier-Valette, C., Re, D., Adjtoutah, Z., Seitz-Polski, B., Gounant, V., et al. Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article. Eur J Cancer. 2022; 162:182-193. Available from: doi:10.1016/j.ejca.2021.12.011
Goshen-Lago T, Waldhorn I, Holland R, Szwarcwort-Cohen M, Reiner-Benaim A, Shachor-Meyouhas Y et al. Serologic status and toxic effects of the SARS-CoV-2 BNT162b2 vaccine in patients undergoing treatment for cancer. JAMA Oncol. 2021: e212675. Available from: doi:10.1001/jamaoncol.2021.2675

Details

Primary Language

English

Subjects

Biochemistry and Cell Biology (Other) , Clinical Sciences , Oncology and Carcinogenesis

Journal Section

Research Article

Authors

Aysun Işıklar ^*
0000-0003-2690-3067
Türkiye

Gül Başaran
0000-0002-0775-6180
Türkiye

Ozde Melisa Celayir
0000-0002-8562-7085
Türkiye

Gülçin Kahraman
0000-0003-1235-5389
Türkiye

Jameela Somanje
0000-0002-6181-6113
Türkiye

Semra Öykü Çolak
0000-0002-8609-9747
Türkiye

Mustafa Serteser
0000-0001-7868-7613
Türkiye

Nurdan Tozun
0000-0001-6487-2551
Türkiye

Early Pub Date

June 14, 2023

Publication Date

July 10, 2023

Submission Date

February 9, 2023

Acceptance Date

May 13, 2023

Published in Issue

Year 2023 Volume: 14 Number: 3

DOI

https://doi.org/10.31067/acusaglik.1247538

IZ

https://izlik.org/JA93YG46TF

Cite

RIS / Bibtex

EndNote

Işıklar A, Başaran G, Celayir OM, Kahraman G, Somanje J, Çolak SÖ, Serteser M, Tozun N (July 1, 2023) Serologic Response to SARS-CoV-2 Vaccine in Patients with Breast Cancer. Acıbadem Üniversitesi Sağlık Bilimleri Dergisi 14 3 332–338.

Öz

Serologic Response to SARS-CoV-2 Vaccine in Patients with Breast Cancer

Abstract

Keywords

Supporting Institution

Project Number

Thanks

References

Details

Primary Language

Subjects

Journal Section

Authors

Early Pub Date

Publication Date

Submission Date

Acceptance Date

Published in Issue

DOI

IZ

Cite